October’s pain management coverage examined postoperative suzetrigine, pharmacist follow-up for cancer-related neuropathic pain, constipation prevention, and counseling patients concerned about prescribed opioids.
Publication|Articles|September 18, 2026
Pharmacy Practice in Focus: Health Systems
- September 2026
- Volume 15
- Issue 5
Bridging the Gap: Pharmacist Experiences Obtaining DEA Licenses
Fact checked by: Ron Panarotti
Pharmacists describe their experiences using DEA certificates for controlled substance prescribing in different practice settings, as well as barriers and opportunities for future expansion.
Advertisement
Advertisement
Pharmacist prescriptive authority has progressed significantly since the first collaborative practice legislation was passed in Washington state in 1979.1 Now, states continue to expand pharmacist prescriptive authority for controlled substances by permitting pharmacists to apply for Drug Enforcement Administration (DEA) controlled-substance licenses.
Related to this article
As kratom questions increase, many pharmacists and other health care professionals may remain unfamiliar it and the potential risks.
Payer requirements, prescriber habits, and operational realities ultimately determine which ICI patients receive.
Pharmacy Times previews enlicitide, survodutide, diet and heart failure risk, and pharmacist-led HF care ahead of the AHA Scientific Sessions in Chicago.
At the 2026 ASTCT Gene Therapy Summit, experts highlighted how chronic pain, psychological challenges, and neurologic complications may persist despite successful treatment.
Twice-daily metronidazole dosing had outcomes comparable with those of thrice-daily dosing for confirmed anaerobic infections, minimizing drug exposure and cost while maintaining clinical efficacy.
Two Kidney Week 2026 posters suggest remnant cholesterol–based markers may help stratify CKD severity and cardiovascular death risk on hemodialysis.
In a Korean cohort of 1861 patients with nondialysis CKD, intake below 0.6 g/kg per day was linked to more kidney failure and higher all-cause mortality.
Advertisement
Advertisement